Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Tamborrini, Marco ^a,b   Stoffel, Sabine A ^c,d   Westerfeld, Nicole ^c   Amacker, Mario ^c   Theisen, Michael ^e   Zurbriggen, Rinaldo ^c,f   Pluschke, Gerd ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Pevion Biotech AG   (Switzerland)

^d Mymetics SA   (Switzerland)

^e STATENS SERUM INSTITUT   (Denmark)

^f LONZA AG   (Switzerland)

Author keywords

GMZ2 immunogenicity; Influenza virosomes; Plasmodium falciparum malaria; Vaccine candidate

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; CHIMERIC PROTEIN; GLUTAMATE RICH PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOLOGICAL ADJUVANT; IMMUNOPOTENTIATING RECONSTITUTED INFLUENZA VIROSOME; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 3; MONTANIDE ISA 720; PHOSPHATIDYLETHANOLAMINE; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN GMZ2; UNCLASSIFIED DRUG; VIROSOME; DRUG DERIVATIVE; GLUTAMATE RICH PROTEIN, PLASMODIUM; GLUTAMATE-RICH PROTEIN, PLASMODIUM; IMMUNOGLOBULIN G; MANNITOL; MANNITYL OLEATE; MEROZOITE SURFACE PROTEIN 3, PLASMODIUM; OLEIC ACID; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT VACCINE; VIROSOME VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNE DEFICIENCY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IN VITRO STUDY; INBRED STRAIN; MALARIA FALCIPARUM; MOUSE; NONHUMAN; OUTBRED STRAIN; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CROSS REACTIONS; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MALARIA VACCINES; MANNITOL; MICE; OLEIC ACIDS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VACCINES, VIROSOME;

EID: 83255162697     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-359     Document Type: Article

References (45)

1. Coadaptation and malaria control. Tosta CE, Mem Inst Oswaldo Cruz 2007 102 385 404 10.1590/S0074-02762007005000042 17568946 (Pubitemid 46876449)
2. Mosquito behavior and vector control. Pates H, Curtis C, Annu Rev Entomol 2005 50 53 70 10.1146/annurev.ento.50.071803.130439 15355233
3. Malaria vaccine design: immunological considerations. Good MF, Doolan DL, Immunity 2010 4 555 566
4. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, Madsen SM, Druilhe P, Vaccine 2004 22 1188 1198 10.1016/j.vaccine.2003.09.017 15003647 (Pubitemid 38296662)
5. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P, Blood 1994 84 1594 1602 8068948 (Pubitemid 24273030)
6. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S, Jepsen S, Druilhe P, Infect Immun 1998 66 11 17 9423833 (Pubitemid 28018795)
7. Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. Badell E, Oeuvray C, Moreno A, Soe S, van Rooijen N, Bouzidi A, Druilhe P, J Exp Med 2000 192 1653 1659 10.1084/jem.192.11.1653 11104807
8. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P, Infect Immun 2000 68 2617 2620 10.1128/IAI.68.5.2617-2620.2000 10768952 (Pubitemid 30253834)
9. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S, Nkrumah FK, Theander TG, Hviid L, J Infect Dis 2000 181 1202 1205 10.1086/315341 10720556 (Pubitemid 30194517)
10. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Theisen M, Dodoo D, Toure-Balde A, Soe S, Corradin G, Koram KK, Kurtzhals JA, Hviid L, Theander T, Akanmori B, Ndiaye M, Druilhe P, Infect Immun 2001 69 5223 5239 10.1128/IAI.69.9.5223-5229.2001 11500389 (Pubitemid 32786451)
11. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, Miller LH, Stowers AW, J Infect Dis 2002 185 657 664 10.1086/339187 11865423 (Pubitemid 34171471)
12. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S, Audran R, Bouzidi A, Oeuvray C, Roussilhon C, PLoS Med 2005 2 344 10.1371/journal.pmed.0020344 16262450 (Pubitemid 41735781)
13. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. Roussilhon C, Oeuvray C, Müller-Graf C, Tall A, Rogier C, Trape JF, Theisen M, Balde A, Pérignon JL, Druilhe P, PLoS Med 2007 4 320 10.1371/journal.pmed.0040320 18001147 (Pubitemid 350220532)
14. Cationic liposomes formulated with synthetic mycobacterial cord factor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, Werninghaus K, Kirschning C, Lang R, Christensen D, Theisen M, Follmann F, Andersen P, PLoS ONE 2008 3 3116 10.1371/journal.pone.0003116 18776936
15. Vaccine immunopotentiators of the future. Schijns VE, Degen WG, Clin Pharmacol Ther 2007 82 750 755 10.1038/sj.clpt.6100394 17914440 (Pubitemid 350114822)
16. Aluminium compounds for use in vaccines. Lindblad EB, Immunol Cell Biol 2004 82 497 505 10.1111/j.0818-9641.2004.01286.x 15479435 (Pubitemid 39421059)
17. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orcutt A, Muratova O, Awkal M, Zhou H, Wang J, Stowers A, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP, Infect Immun 2005 73 3677 3685 10.1128/IAI.73.6.3677-3685.2005 15908397 (Pubitemid 40745912)
18. Phase I trial of two recombinant vaccines containing the 19 kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, Krzych U, Palmer DR, Egan A, Diggs C, Ballou WR, Hall BF, Kaslow D, Vaccine 1999 18 531 539 10.1016/S0264-410X(99)00221-2 10519944 (Pubitemid 29462611)
19. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, Gordon DM, Schneider I, Wirtz RA, Young JF, Reeve P, Chulaya JD, Lancet 1987 1 1277 1281 2884410 (Pubitemid 17072190)
20. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity. Amador R, Moreno A, Valero V, Murillo L, Mora AL, Rojas M, Rocha C, Salcedo M, Guzman F, Espejo F, Nunez F, Patarroyo ME, Vaccine 1992 10 179 184 10.1016/0264-410X(92)90009-9 1557934
21. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V, Expert Rev Vaccines 2002 1 111 118 10.1586/14760584.1.1.111 12908518 (Pubitemid 36686885)
22. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Pye D, Vandenberg KL, Dyer SL, Irving DO, Goss NH, Woodrow GC, Saul A, Alving CR, Richards RL, Ballou WR, Wu MJ, Skoff K, Anders RF, Vaccine 1997 15 1017 2103 10.1016/S0264-410X(96)00289-7 9261951 (Pubitemid 27308580)
23. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, Cloonan N, Rzepczyk C, Smillie A, Anderson K, Pombo D, Allworth A, Eisen D, Anders R, Saul A, Vaccine 2000 18 1925 1931 10.1016/S0264-410X(99)00444-2 10699342 (Pubitemid 30122856)
24. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Lawrence GW, Saul A, Giddy AJ, Kemp R, Pye D, Vaccine 1997 15 176 178 10.1016/S0264-410X(96)00150-8 9066035 (Pubitemid 27091248)
25. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WR, Reber R, Stürchler D, Vaccine 1999 17 3145 3159 10.1016/S0264-410X(99)00175-9 10462251 (Pubitemid 29366996)
26. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP, J Infect Dis 2002 185 820 827 10.1086/339342 11920300 (Pubitemid 34226210)
27. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, Schroller S, Vounatsou P, Mueller MM, Tanner M, Zurbriggen R, PLoS One 2007 2 1018 10.1371/journal. pone.0001018 17925866 (Pubitemid 351560148)
28. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, Poulton I, Correa S, Hutchings C, Berthoud T, Dunachie S, Andrews L, Williams JL, Sinden R, Gilbert SC, Pluschke G, Zurbriggen R, Hill AV, PLoS One 2008 3 1493 10.1371/journal.pone.0001493 18231580 (Pubitemid 351827205)
29. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Bovier PA, Farinelli T, Loutan L, Vaccine 2005 23 2424 2429 10.1016/j.vaccine.2004.11.024 15752828 (Pubitemid 40332514)
30. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. Mayorga Pérez O, Herzog C, Zellmeyer M, Loáisiga A, Frösner G, Egger M, J Infect Dis 2003 188 671 677 10.1086/377309 12934183 (Pubitemid 37115180)
31. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Kammer AR, Amacker M, Rasi S, Westerfeld N, Gremion C, Neuhaus D, Zurbriggen R, Vaccine 2007 25 7065 7074 10.1016/j.vaccine.2007.07.052 17766014 (Pubitemid 47464681)
32. Matile H, Pink J, Immunological Methods San Diego: Academic Press, Inc, Lefkovits I, Benvenuto P, 1990 221 234
33. Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine. Tamborrini M, Mueller MS, Stoffel SA, Westerfeld N, Vogel D, Boato F, Zurbriggen R, Robinson JA, Pluschke G, Malar J 2009 8 314 10.1186/1475-2875-8-314 20042100
34. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - a GLURP-MSP3 fusion protein malaria vaccine candidate. Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RF, Vedvick TS, Ireton G, Carter D, Reed SG, Theisen M, Vaccine 2011 29 3284 3292 10.1016/j.vaccine.2011.02.022 21349366
35. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Esen M, Kremsner PG, Schleucher R, Gässler M, Imoukhuede EB, Imbault N, Leroy O, Jepsen S, Knudsen BW, Schumm M, Knobloch J, Theisen M, Mordmüller B, Vaccine 2009 27 6862 6868 10.1016/j.vaccine.2009.09.011 19755144
36. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. Carvalho LJ, Alves FA, Bianco C Jr, Oliveira SG, Zanini GM, Soe S, Druilhe P, Theisen M, Muniz JA, Daniel-Ribeiro CT, Clin Diagn Lab Immunol 2005 2 242 248 (Pubitemid 41094447)
37. Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A. Kaba SA, Price A, Zhou Z, Sundaram V, Schnake P, Goldman IF, Lal AA, Udhayakumar V, Todd CW, Clin Vaccine Immunol 2008 15 1674 1683 10.1128/CVI.00164-08 18784343
38. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR, RTS, S Malaria Vaccine Evaluation Group, J Infect Dis 2001 183 640 647 10.1086/318534 11170991 (Pubitemid 32147521)
39. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Toledo H, Baly A, Castro O, Resik S, Laferté J, Rolo F, Navea L, Lobaina L, Cruz O, Míguez J, Serrano T, Sierra B, Pérez L, Ricardo ME, Dubed M, Lubián AL, Blanco M, Millán JC, Ortega A, Iglesias E, Pentán E, Martín Z, Pérez J, Díaz M, Duarte CA, Vaccine 2001 19 4328 4336 10.1016/S0264-410X(01)00111-6 11457560 (Pubitemid 32703655)
40. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP, Vaccine 2003 22 30 41 10.1016/S0264-410X(03)00536-X 14604568 (Pubitemid 37357150)
41. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, Imoukhuede E, Jepsen S, Ofori-Anyinam O, Faber B, Kocken CH, Arnold M, Walraven V, Teelen K, Roeffen W, de Mast Q, Ballou WR, Cohen J, Dubois MC, Ascarateil S, van der Ven A, Thomas A, Sauerwein R, PLoS One 2008 3 3960 10.1371/journal.pone. 0003960 19093004
42. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, Rzepczyk C, Martin LB, Taylor D, Eisen DP, Irving DO, Pye D, Crewther PE, Hodder AN, Murphy VJ, Anders RF, Vaccine 2005 23 3076 3083 10.1016/j.vaccine.2004.09.040 15811655 (Pubitemid 40462448)
43. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon. Mordmüller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C, Mürbeth RE, Chilengi R, Noor R, Kilama WL, Imoukhuede EB, Imbault N, Leroy O, Theisen M, Jepsen S, Milligan P, Fendel R, Kremsner PG, Issifou S, Vaccine 2010
44. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. Bélard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, Fendel R, Martinez de Salazar P, Mürbeth RE, Milligan P, Imbault N, Imoukhuede EB, Theisen M, Jepsen S, Noor RA, Okech B, Kremsner PG, Mordmüller B, PLoS One
45. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: a randomized Phase 1b trial in semi-immune adults & children. Cech PG, Aebi T, Abdallah MS, Mpina M, Machunda EB, Westerfeld N, Stoffel SA, Zurbriggen R, Pluschke G, Tanner M, Daubenberger C, Genton B, Abdulla S, PLoS One 2011 7 22273